Site icon Hot Paths

Zentalis and PureTech get Fast Track Designation from FDA for their cancer treatments

Press Room
Modern Medical Research Laboratory: Portrait of Latin and Black Young Scientists Using Microscope, Digital Tablet, Doing Sample Analysis, Talking. Diverse Team of Specialists work in Advanced Lab

gorodenkoff/iStock via Getty Images

  • Zentalis Pharmaceuticals (NASDAQ:ZNTL) announced that the FDA has granted Fast Track Designation to azenosertib for treating platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with elevated Cyclin E1 protein levels.
  • PureTech Health (NASDAQ:PRTC) also said that the FDA has
Exit mobile version